CN113164438B - 治疗化疗难治性癌症的新联合用药方案 - Google Patents

治疗化疗难治性癌症的新联合用药方案 Download PDF

Info

Publication number
CN113164438B
CN113164438B CN201980066957.7A CN201980066957A CN113164438B CN 113164438 B CN113164438 B CN 113164438B CN 201980066957 A CN201980066957 A CN 201980066957A CN 113164438 B CN113164438 B CN 113164438B
Authority
CN
China
Prior art keywords
cancer
administered
pharmaceutically acceptable
gemcitabine
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980066957.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN113164438A (zh
Inventor
李嘉强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1Globe Biomedical Co Ltd
Original Assignee
1Globe Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 1Globe Biomedical Co Ltd filed Critical 1Globe Biomedical Co Ltd
Priority to CN202510203958.9A priority Critical patent/CN120168498A/zh
Publication of CN113164438A publication Critical patent/CN113164438A/zh
Application granted granted Critical
Publication of CN113164438B publication Critical patent/CN113164438B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980066957.7A 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案 Active CN113164438B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510203958.9A CN120168498A (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811195239 2018-10-12
CN2018111952393 2018-10-12
PCT/CN2019/110904 WO2020074010A1 (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510203958.9A Division CN120168498A (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Publications (2)

Publication Number Publication Date
CN113164438A CN113164438A (zh) 2021-07-23
CN113164438B true CN113164438B (zh) 2025-03-18

Family

ID=70163618

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980066957.7A Active CN113164438B (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案
CN202510203958.9A Pending CN120168498A (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510203958.9A Pending CN120168498A (zh) 2018-10-12 2019-10-12 治疗化疗难治性癌症的新联合用药方案

Country Status (15)

Country Link
US (2) US12257227B2 (https=)
EP (1) EP3865130A4 (https=)
JP (2) JP7513286B2 (https=)
CN (2) CN113164438B (https=)
AU (1) AU2019357933B2 (https=)
BR (1) BR112021006898A2 (https=)
CA (1) CA3115869A1 (https=)
EA (1) EA202190771A1 (https=)
IL (1) IL282228A (https=)
MX (1) MX2021004151A (https=)
PH (1) PH12021550815A1 (https=)
SG (1) SG11202103707TA (https=)
TW (1) TWI848990B (https=)
WO (1) WO2020074010A1 (https=)
ZA (1) ZA202102494B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7513286B2 (ja) * 2018-10-12 2024-07-09 １グローブ バイオメディカル カンパニー， リミテッド 化学療法難治性がんの治療のための新しい併用薬方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20160625T1 (hr) 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
WO2011116398A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Novel compounds and compositions for targeting cancer stem cells
ES2987670T3 (es) 2010-03-19 2024-11-15 1Globe Biomedical Co Ltd Métodos novedosos para actuar sobre células madre cancerosas
JP2014511384A (ja) 2011-03-04 2014-05-15 ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッド 疾患治療のための４，９−ジヒドロキシ−ナフト［２，３−ｂ］フランの新規エステル
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
CA2908380A1 (en) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Methods for treating cancer
JP2018511643A (ja) 2015-04-17 2018-04-26 ボストン バイオメディカル， インコーポレイテッド 癌を治療するための方法
CN107766371B (zh) * 2016-08-19 2023-11-17 中兴通讯股份有限公司 一种文本信息分类方法及其装置
JP7513286B2 (ja) * 2018-10-12 2024-07-09 １グローブ バイオメディカル カンパニー， リミテッド 化学療法難治性がんの治療のための新しい併用薬方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017132049A1 (en) * 2016-01-20 2017-08-03 Boston Biomedical, Inc. Methods for treating cancer
TW201731500A (zh) * 2016-01-20 2017-09-16 波士頓生醫公司 用於治療癌症的方法

Also Published As

Publication number Publication date
ZA202102494B (en) 2023-01-25
WO2020074010A1 (zh) 2020-04-16
EA202190771A1 (ru) 2021-09-07
AU2019357933A1 (en) 2021-05-20
US20210393571A1 (en) 2021-12-23
EP3865130A4 (en) 2022-07-20
IL282228A (en) 2021-05-31
EP3865130A1 (en) 2021-08-18
PH12021550815A1 (en) 2021-10-04
CA3115869A1 (en) 2020-04-16
US20250235425A1 (en) 2025-07-24
SG11202103707TA (en) 2021-05-28
KR20210076951A (ko) 2021-06-24
MX2021004151A (es) 2021-09-08
US12257227B2 (en) 2025-03-25
JP2022504760A (ja) 2022-01-13
TWI848990B (zh) 2024-07-21
BR112021006898A2 (pt) 2021-07-20
JP2024123152A (ja) 2024-09-10
JP7513286B2 (ja) 2024-07-09
CN120168498A (zh) 2025-06-20
AU2019357933B2 (en) 2023-11-23
TW202027738A (zh) 2020-08-01
CN113164438A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
US20180085341A1 (en) Methods for treating cancer
US20190224157A1 (en) Methods for treating cancer
US10646464B2 (en) Methods for treating cancer
US20190231735A1 (en) Methods for treating cancer
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
EP3283070A1 (en) Methods for treating cancer
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer
KR102960038B1 (ko) 화학요법 불응성 암을 치료하기 위한 신규한 조합 방안
HK40124738A (zh) 治疗化疗难治性癌症的新联合用药方案
HK40048413A (en) New combination solution for treating chemotherapy refractory cancer
EA046190B1 (ru) Новое комбинированное решение для лечения рака, резистентного к химиотерапии

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40047114

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant